Single‐cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation
The Journal of Gene Medicine · 2024
DOI: 10.1002/jgm.3658 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2024. Verfasst von Long Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Liaoning University of Traditional Chinese Medicine, Shenyang, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Liaoning Province Science and Technology Planning Project.
Abstract (Originalsprache)
Background
Aberrant activation of the phosphatidlinositol 3‐kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway has been shown to play an important role in lung adenocarcinoma (LUAD). The effect of KRAS mutations, one of the important signatures of LUAD, on the PI3K/AKT/mTOR pathway in LUAD remains unclear.
Methods
The Seurat package and principal component analysis were used for cell categorization of single‐cell RNA sequencing data of LUAD. The AUCell score was used to assess the activity of the PI3K/AKT/mTOR pathway. Meanwhile, using the gene expression profiles and mutation profiles in the The Cancer Genome Atlas dataset, LUAD patients were categorized into KRAS‐mutant (KRAS‐MT) and KRAS‐wild‐types (KRAS‐WT), and the corresponding enrichment scores were calculated using gene set enrichment analysis analysis. Finally, the subpopulation of cells with the highest pathway activity was identified, the copy number variation profile of this subpopulation was inscribed using the inferCNV package and the CMap database was utilized to make predictions for drugs targeting this subpopulation.
Results
There is higher PI3K/AKT/mTOR pathway activity in LUAD epithelial cells with KRAS mutations, and high expression of KRAS, PIK3CA, AKT1 and PDPK1. In particular, we found significantly higher levels of pathway activity and associated gene expression in KRAS‐MT than in KRAS‐WT. We identified the highest pathway activity on a subpopulation of GRB2 + epithelial cells and the presence of amplified genes within its pathway. Finally, drugs were able to target GRB2 + epithelial cell subpopulations, such as wortmannin, palbociclib and angiogenesis inhibitor.
Conclusions
The present study provides a basic theory for the activation of the PI3K/AKT/mTOR signaling pathway as a result of KRAS mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Traditional Chinese Medicine, Liaoning University of Traditional Chinese Medicine, Shenyang, China.
- Department of Oncology, General Hospital of Northern Theater Command, Shenyang, China.
- Department of Thoracic Surgery, General Hospital of Northern Theater Command, Shenyang, China.
- TCM Innovation Engineering Technology Center, Key Laboratory of Ministry of Education for TCM Viscera-State Theory and Applications, Liaoning University of Traditional Chinese Medicine, Shenyang, China.
Förderung
- Liaoning Province Science and Technology Planning Project
Zitieren
APA
Xu, L., Ding, R., Song, S., Liu, J., Li, J., Ju, X., & Ju, B. (2024). Single‐cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3658
Vancouver
Xu L, Ding R, Song S, Liu J, Li J, Ju X, et al. Single‐cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation. The Journal of Gene Medicine. 2024. doi:10.1002/jgm.3658
BibTeX
@article{Xu2024,
author = {Xu, Long and Ding, Renquan and Song, Shuxi and Liu, Junling and Li, Jingyu and Ju, Xing and Ju, Baozhao},
title = {Single‐cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation},
journal = {The Journal of Gene Medicine},
year = {2024},
doi = {10.1002/jgm.3658}
}
EUVIMED